DELRAY BEACH, Fla., Sept. 27, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today a summary of its highlights for the third quarter of 2016.
- PositiveID was awarded a follow-on contract from the U.S. Department of the Interior on behalf of the U.S. Department of Homeland Security Science & Technology Directorate for the SenseNet Program Phase II, in conjunction with its partner ENSCO.
- The Company announced that it is conducting a pilot study with seqID inc using PositiveID's Firefly Dx polymerase chain reaction ("PCR") breadboard prototype pathogen detection system ("prototype system") to detect genetically modified organisms for the agricultural market.
- The Company completed its acquisition of Thermomedics Inc., the designer and marketer of the
Caregiver® infrared, non-contact thermometer, which is FDA-cleared for clinical use.
- PositiveID announced that it expects to launch a Bluetooth® version of its FDA-cleared Caregiver® infrared, non-contact thermometer by early 2017, to connect wirelessly to electronic health record (EHR) systems and other hospital equipment such as patient monitoring stations.
- The Company announced that Caregiver outperformed a temporal artery thermometer in every category evaluated during a Veterans Affairs San Diego Healthcare System study of Post Anesthesia Care Unit ("PACU") patients.
- PositiveID added Paul Schaudies, Ph.D., Co-Founder and CEO of GenArraytion, to its Board of Advisors. PositiveID has successfully detected the Zika virus on its Firefly Dx prototype system using GenArraytion's Zika assay, the first commercially available, multi-target, PCR-based molecular test to identify the Zika virus, its Aedes Aegypti MultiFLEX™ PCR test.
- During the third quarter of 2016 bookings for vehicle production and modification at the Company's E-N-G-Mobile Systems ("ENG") subsidiary grew approximately 170% over the quarterly average for the first two quarters of 2016.
"We continue to make strides to expand and improve operationally in all areas of our business, and we are particularly proud of the follow-on contract award we received for the second phase of the DHS SenseNet program, which, we believe, further validates our Firefly Dx technology," stated
William J. Caragol, Chairman and CEO of PositiveID. "We believe our product portfolio, which has grown significantly following our acquisitions of Thermomedics and ENG in late 2015, represents best-in-class technologies in each of the markets we serve, and are confident these acquisitions will continue to benefit our Company for the remainder of 2016 and beyond."
PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per
test. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings
of $250 or more per year per device in probe cover supplies alone.
E-N-G Mobile Systems ("ENG") is a leader in the mobile laboratory market, which is a growing segment of the specialty vehicle market as concerns over food and environment contamination, and biological and chemical weapons increase. ENG has built over 400 mobile labs, more than any other specialty vehicle manufacturer, designed for chemical and biological detection, monitoring and analysis. ENG, which has been in business for almost 40 years, further differentiates itself from its competitors with its team of scientists who work in conjunction with the design engineers and shop personnel to deliver the most advanced mobile labs available.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit
http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the
likelihood that the Company expects to launch a Bluetooth® version of its FDA-cleared Caregiver® infrared, non-contact thermometer by early 2017, to connect wirelessly to EHR systems and other hospital equipment such as patient monitoring stations; the likelihood that follow-on contract award the Company received for the second phase of the DHS SenseNet program further validates its Firefly Dx technology; the likelihood that the Company's product portfolio represents best-in-class technologies in each of the markets it serves; the likelihood that the acquisitions of Thermomedics and ENG will continue to benefit the Company for the remainder of 2016 and beyond; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; constitute "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on August 12, 2016, May 16,
2016, and November 12, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
PositiveID CorporationAllison Tomek
Source: PositiveID Corporation
News Provided by Acquire Media